TAE684 (NVP-TAE684)

Catalog No.S1108

TAE684 (NVP-TAE684) is a potent and selective ALK inhibitor with IC50 of 3 nM in a cell-free assay, 100-fold more sensitive for ALK than InsR.

Price Stock Quantity  
USD 160 In stock
USD 290 In stock
USD 770 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

TAE684 (NVP-TAE684) Chemical Structure

TAE684 (NVP-TAE684) Chemical Structure
Molecular Weight: 614.2

Validation & Quality Control

4 customer reviews :

Quality Control & MSDS

Related Compound Libraries

ALK Inhibitors with Unique Features

  • Non-specific ALK Inhibitor

    GSK1838705A IGF-1R, IC50=2.0 nM; IR, IC50=1.6 nM, ALK, IC50=0.5 nM.

  • Most Potent ALK Inhibitor

    Ceritinib (LDK378) ALK, IC50=0.2 nM.

  • FDA-approved ALK Inhibitor

    Crizotinib (PF-02341066) Approved by FDA for non-small cell lung carcinoma (NSCLC).

  • Newest ALK Inhibitor

    ASP3026 Novel and selective inhibitor for ALK with IC50 of 3.5 nM.

Product Information

  • Compare ALK Inhibitors
    Compare ALK Products
  • Research Area
  • TAE684 (NVP-TAE684) Mechanism

Product Description

Biological Activity

Description TAE684 (NVP-TAE684) is a potent and selective ALK inhibitor with IC50 of 3 nM in a cell-free assay, 100-fold more sensitive for ALK than InsR.
Targets ALK [1]
(Cell-free assay)
IC50 3 nM
In vitro TAE684 does not exhibit significant cross-reactivity against other kinases. TAE684 potently inhibits the proliferation of Ba/F3 NPM-ALK cells with IC50 of 3 nM, without affecting the survival of Ba/F3 cells even at 1 μM. TAE684 also inhibits proliferation of NPM-ALK-expressing human ALCL cell lines including Karpas-299 and SU-DHL-1 with IC50 of 2–5 nM. Molecular modeling reveals that L258 may be one of the major kinase-selectivity determinants for TAE684. TAE684 treatment results in a rapid and sustained inhibition of phosphorylation of NPM-ALK. TAE684 induces apoptosis and G1 phase arrest in NPM-ALK-expressing Ba/F3 cells and ALCL patient cell lines. [1] TAE684 markedly overcomes Crizotinib-resistance in H3122 CR cells, harboring the fusion oncogene EML4-ALK, decreasing cell growth, suppressing ALK phosphorylation and inducing apoptosis.[2] Neurite outgrowth induced by expression of the mALK R1279Q mutant could be completely inhibited by TAE684 at 30 nM. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
SCC-3MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{DLXmlEPTB;MD6wNFAxPjB|IN88US=>MUHTRW5ITVJ?
SF539MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3rLT2lEPTB;MD6wNFA2PjRizszNM{PPeXNCVkeHUh?=
DELMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXLDOod6UUN3ME2wMlAxODl{NzFOwG0>NGPGUXhUSU6JRWK=
NB1NH;lNY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlrzTWM2OD1yLkCwNVYzKM7:TR?=NEnWU3FUSU6JRWK=
SRNYPTfGJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3hdZFKSzVyPUCuNFAzPzdizszNMUDTRW5ITVJ?
KARPAS-299MmPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\jSmlEPTB;MD6wNlM5PCEQvF2=NULRSXRGW0GQR1XS
MHH-CALL-2MoLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mne1TWM2OD1yLkCyPVUzKM7:TR?=MX;TRW5ITVJ?
SU-DHL-1NFvKbWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlzJTWM2OD1yLkC0PFY2KM7:TR?=M4fzNnNCVkeHUh?=
A4-FukMlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRTBwMEW1OlUh|ryPNETpd49USU6JRWK=
EW-1MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXHyNnA3UUN3ME2wMlExOjV4IN88US=>NYPD[3FoW0GQR1XS
NOS-1MmXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoLaTWM2OD1yLkGwNlk1KM7:TR?=M3rrUXNCVkeHUh?=
EW-16M{KxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV\TZ|k1UUN3ME2wMlExPTZ6IN88US=>MVnTRW5ITVJ?
TE-11MoSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\RboluUUN3ME2wMlE3ODl4IN88US=>NX\NVVE3W0GQR1XS
SW982M{fSUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1fieGlEPTB;MD6xOlQ4QCEQvF2=MnjQV2FPT0WU
LAN-6MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPYdHZKSzVyPUCuNVc1PDNizszNNXzBVolDW0GQR1XS
MZ1-PCM3;T[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIPxNoRKSzVyPUCuNVc5OzVizszNNFLZNlZUSU6JRWK=
KS-1NGn5S5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\jSGlEPTB;MD6xPVM1OyEQvF2=MX7TRW5ITVJ?
PSN1M4XlXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{PaOGlEPTB;MD6xPVY{OSEQvF2=M4XKd3NCVkeHUh?=
LC-2-adMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjWfYROUUN3ME2wMlE6Pjl{IN88US=>MVXTRW5ITVJ?
COLO-320-HSRNES4TFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTBwMUm3O|Yh|ryPNETCVHlUSU6JRWK=
OPM-2M4\yR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{PHUGlEPTB;MD6yNlY3QSEQvF2=NWj1NVVIW0GQR1XS
SK-NEP-1M{DsRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUXrXG5UUUN3ME2wMlI{PTJ2IN88US=>NX;JW48{W0GQR1XS
ALL-POMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmnwTWM2OD1yLkK0OVI1KM7:TR?=MkSxV2FPT0WU
CMKNYSyfYFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn\KTWM2OD1yLkK1OVMh|ryPNUfzclVTW0GQR1XS
NCI-H1648NUnZ[HBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4\T[GlEPTB;MD6yO|g2PSEQvF2=MnrmV2FPT0WU
SIG-M5NWf2UlhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTBwMkmxOVkh|ryPMY\TRW5ITVJ?
TGBC24TKBNFLvTZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1rwVWlEPTB;MD6zNFIyQCEQvF2=M3zCTnNCVkeHUh?=
DOHH-2NXv1V4JuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlPFTWM2OD1yLkOxNlA1KM7:TR?=NXXHfmg{W0GQR1XS
NB69NVTVVW1{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTBwM{G3PFch|ryPM4[y[nNCVkeHUh?=
MFH-inoNGHUPVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlHsTWM2OD1yLkOyOVI{KM7:TR?=MoK3V2FPT0WU
KP-N-RT-BM-1NHu3fJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFvYeW5KSzVyPUCuN|MyOjNizszNNXHHcWNNW0GQR1XS
MONO-MAC-6MkDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXW2b4NOUUN3ME2wMlM{OjlzIN88US=>NFPKTWNUSU6JRWK=
ATN-1M1LWRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTBwM{OzNFMh|ryPMXPTRW5ITVJ?
NTERA-S-cl-D1NH3FfoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2XQe2lEPTB;MD6zN|M6PiEQvF2=MknWV2FPT0WU
L-540MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYr5VIJCUUN3ME2wMlM3QTh6IN88US=>MmPiV2FPT0WU
GB-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUHw[2tHUUN3ME2wMlM5QDZ5IN88US=>M{HtdHNCVkeHUh?=
MV-4-11MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHPSSnlKSzVyPUCuN|k1PDZizszNMV3TRW5ITVJ?
KG-1MoHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUjT[W9RUUN3ME2wMlM6PTZzIN88US=>NFPtUJNUSU6JRWK=
OVCAR-4MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUfJR|UxRTBwNEC1Olkh|ryPMnewV2FPT0WU
NEC8MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTBwNEGyPVIh|ryPNUTBemc4W0GQR1XS
SK-MM-2MmrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2jve2lEPTB;MD60NVYxQSEQvF2=NGH0XoVUSU6JRWK=
TE-8NUHoZ2RLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVnDRVBtUUN3ME2wMlQzQDhizszNM{HvPHNCVkeHUh?=
697NHnsWJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmPzTWM2OD1yLkSzNlE2KM7:TR?=MYfTRW5ITVJ?
NB14NYDkN2ZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTBwNEO4NlYh|ryPNFzxNYpUSU6JRWK=
GDM-1NEOxTHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYm5NmJ5UUN3ME2wMlQ4OTF4IN88US=>M17pbXNCVkeHUh?=
HUTU-80NHS3PFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTBwNEezO|Uh|ryPMYjTRW5ITVJ?
HL-60NVjQW2toT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmryTWM2OD1yLkS4NVQzKM7:TR?=NYq4S5BWW0GQR1XS
OCI-AML2M3P0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoK0TWM2OD1yLkS4N|I5KM7:TR?=NX7md4FvW0GQR1XS
ML-2NFj5VXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGTvVHVKSzVyPUCuOFkxOzFizszNNY\EcWRmW0GQR1XS
ES4M3yzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnnxTWM2OD1yLkS5NVA6KM7:TR?=NV3xeVl5W0GQR1XS
NCI-H747NIrxcGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGqzfmFKSzVyPUCuOFk5QSEQvF2=MWDTRW5ITVJ?
RL95-2MmTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1PX[GlEPTB;MD61NFEyOiEQvF2=M2H4fHNCVkeHUh?=
TE-15MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUjxb4pjUUN3ME2wMlUyOTJ2IN88US=>MUjTRW5ITVJ?
TE-12MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4P3SmlEPTB;MD61N|M1QSEQvF2=Ml3oV2FPT0WU
LB1047-RCCNIDyUXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTBwNUS1OFkh|ryPMo\VV2FPT0WU
LB831-BLCNVG2PXBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mlu0TWM2OD1yLkW1NFI{KM7:TR?=MlPUV2FPT0WU
NCI-H1355MlPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVjJR|UxRTBwNUWxPFQh|ryPMlPKV2FPT0WU
CTV-1Ml33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVHGfFM2UUN3ME2wMlU2PjJ2IN88US=>NH3lfXFUSU6JRWK=
RXF393NXzVbFdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGnNNIxKSzVyPUCuOVU4QTRizszNMUnTRW5ITVJ?
SW872NGC1fnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MorhTWM2OD1yLkW2O|I1KM7:TR?=NV;UWm9MW0GQR1XS
MPP-89NFzlT2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\6TmlEPTB;MD61O|g5PCEQvF2=MXvTRW5ITVJ?
RPMI-8226MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXTJR|UxRTBwNkO1NlYh|ryPM1HjfnNCVkeHUh?=
LS-1034NG[1RVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWrFSJZwUUN3ME2wMlY{PThizszNNUP3PXlRW0GQR1XS
SJSA-1MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFTvc|hKSzVyPUCuOlM4OjVizszNMXrTRW5ITVJ?
HOP-62NHXv[mVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPkTWM2OD1yLk[1NFM{KM7:TR?=MUfTRW5ITVJ?
KGNMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTBwNk[xOlgh|ryPMVPTRW5ITVJ?
D-336MGM{foVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4nBeWlEPTB;MD62OlE3QSEQvF2=MU\TRW5ITVJ?
LS-411NMlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGLCUWxKSzVyPUCuOlc1PjJizszNM171ZnNCVkeHUh?=
TE-1MnjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGf6[ZhKSzVyPUCuOlkxPzRizszNNXTVO|ZFW0GQR1XS
LB996-RCCMnnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkHOTWM2OD1yLk[5N|g6KM7:TR?=NH;EO2dUSU6JRWK=
TE-10NVjaVY1jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4PkWGlEPTB;MD63NVQ6PiEQvF2=NXTYVmtWW0GQR1XS
NCI-SNU-16MoTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\pTWM2OD1yLkeyOlY1KM7:TR?=MY\TRW5ITVJ?
ES8MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFGxNoVKSzVyPUCuO|Q6PzVizszNMmXZV2FPT0WU
COLO-800NYC5Wm5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTBwN{[2PVUh|ryPM1TD[XNCVkeHUh?=
ES6MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoP0TWM2OD1yLke3OVU6KM7:TR?=NFjmSZFUSU6JRWK=
L-363NWC2ZlZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vXNGlEPTB;MD64NlM4PSEQvF2=M1W1V3NCVkeHUh?=
NMC-G1M3TVemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTBwOEOyN|Mh|ryPMkjxV2FPT0WU
LU-134-AM{\qZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrJTWM2OD1yLkizPVEzKM7:TR?=Mki2V2FPT0WU
SF268MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{DuRmlEPTB;MD64OFA1OiEQvF2=NWDk[XpEW0GQR1XS
KARPAS-45MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M13ZTGlEPTB;MD64OFI3OyEQvF2=M{PWfHNCVkeHUh?=
TGWM1fBfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLK[pBPUUN3ME2wMlg2QDZ|IN88US=>M4\PN3NCVkeHUh?=
CHP-126NHnyUHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mmf5TWM2OD1yLki1PVU4KM7:TR?=MmXxV2FPT0WU
MOLT-16NWexU3lCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1TLd2lEPTB;MD64O|U5QSEQvF2=MYXTRW5ITVJ?
LB771-HNCMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYrlW4xYUUN3ME2wMlg6PzV5IN88US=>NFrSbVhUSU6JRWK=
NALM-6M1K3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXlTWM2OD1yLkmwO|M6KM7:TR?=M{LSWnNCVkeHUh?=
GCIYMn3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlG2TWM2OD1yLkm1OVI3KM7:TR?=NW\pR4pYW0GQR1XS
IST-MES1M3XLXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV72SZhlUUN3ME2wMlk5QDJ2IN88US=>NIHTeVlUSU6JRWK=
LB2241-RCCM{TZNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NULoZmE5UUN3ME2wMlk5QDRizszNMkPaV2FPT0WU
BL-70MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NITrb4FKSzVyPUCuPVk2OzVizszNNGe2[GhUSU6JRWK=
NB17M2DhNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPYTWM2OD1zLkCwOlM6KM7:TR?=NWTnOFV1W0GQR1XS
LXF-289MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEPQcWZKSzVyPUGuNFMxPzZizszNNFfWOXlUSU6JRWK=
TK10NUDJPGhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRTFwMEWwOlMh|ryPM1LDZnNCVkeHUh?=
K5M1e3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4C4b2lEPTB;MT6wOlI4PCEQvF2=MYfTRW5ITVJ?
NCI-H716MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWjE[mhqUUN3ME2xMlA4OjV7IN88US=>NYW2WGI4W0GQR1XS
HCE-TNF7mfJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV2ybXRWUUN3ME2xMlA5QDF7IN88US=>MUfTRW5ITVJ?
GI-1M1TJSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\WOoVKSzVyPUGuNFk4QThizszNM4HBV3NCVkeHUh?=
KARPAS-422MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{PReGlEPTB;MT6xNFAzOiEQvF2=NFjvPZNUSU6JRWK=
TE-9Moq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\JcGlEPTB;MT6xNVMzQCEQvF2=NFvQR49USU6JRWK=
SF126MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{K2U2lEPTB;MT6xNVU3QCEQvF2=NXLpWI9bW0GQR1XS
BB30-HNCMn6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVrjRZlJUUN3ME2xMlE{OTF{IN88US=>MUfTRW5ITVJ?
NCI-H1304NYjHNY9JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVj3dpJnUUN3ME2xMlE{OzN6IN88US=>MmjpV2FPT0WU
HELMmSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmDHTWM2OD1zLkG0PFk2KM7:TR?=MXrTRW5ITVJ?
HAL-01MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NULXUYw6UUN3ME2xMlE2Ojh|IN88US=>NVrmOW95W0GQR1XS
SK-LMS-1M3TJNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVzuZVBOUUN3ME2xMlE2QTd2IN88US=>MWHTRW5ITVJ?
SW954MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEfwXmlKSzVyPUGuNVk2PjdizszNM1XqPXNCVkeHUh?=
D-283MEDMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTFwMkKzO|kh|ryPM1XSNXNCVkeHUh?=
NCI-H1882NE\CbXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mm[2TWM2OD1zLkKzPFkh|ryPMWDTRW5ITVJ?
GI-ME-NMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXETWM2OD1zLkK1NlA5KM7:TR?=NYLMN2xCW0GQR1XS
SK-PN-DWMn\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH\mZ3pKSzVyPUGuNlY{PDhizszNNXH5T3NqW0GQR1XS
C2BBe1M2PSRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGjRSIJKSzVyPUGuNlkyOTdizszNNXTQVodRW0GQR1XS
A704M{TNVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLjTWM2OD1zLkOyOlg6KM7:TR?=MXLTRW5ITVJ?
KALS-1M1PmU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRTFwM{SwPEDPxE1?MX;TRW5ITVJ?
ETK-1NXj1TVB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRTFwM{S0PFkh|ryPMYHTRW5ITVJ?
LB647-SCLCNFLIN21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmrjTWM2OD1zLkO0PVg3KM7:TR?=NFPsPVVUSU6JRWK=
OCUB-MNI\4dXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH[1R4JKSzVyPUGuN|YyPDNizszNNEDj[FVUSU6JRWK=
NCI-H720MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGH2[|NKSzVyPUGuN|Y{PzhizszNNHSwNHhUSU6JRWK=
NB13NYW2VIdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTFwM{eyPVMh|ryPM13ucHNCVkeHUh?=
GR-STM3\QZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2fTeWlEPTB;MT6zPFc2PyEQvF2=NWTVR3FNW0GQR1XS
DU-4475NGXtZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2LpZWlEPTB;MT60OVg2OyEQvF2=NXHEXmI1W0GQR1XS
HCC2157Ml:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTFwNE[2OVkh|ryPNFnjXnpUSU6JRWK=
RKOMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEHpW5hKSzVyPUGuOFk6OjJizszNNVX3PGFPW0GQR1XS
LS-123NGjYfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1L0T2lEPTB;MT61NVU6PCEQvF2=MXzTRW5ITVJ?
NCI-H69MmDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mmm5TWM2OD1zLkW1PFEyKM7:TR?=NV3lfWdZW0GQR1XS
SW962NY\JWldxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEPWe|RKSzVyPUGuOVYyOyEQvF2=NX\UbmNUW0GQR1XS
PF-382M2PGfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTFwNU[5OkDPxE1?NG\qS3FUSU6JRWK=
A101DNEXIdYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mo\ZTWM2OD1zLkW3NVE{KM7:TR?=NH\sbJpUSU6JRWK=
NB10MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{nyTmlEPTB;MT61O|M6OiEQvF2=NYfYVHpGW0GQR1XS
NB5NYjwb3lST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo\VTWM2OD1zLkW4OFc3KM7:TR?=NX60RnJ1W0GQR1XS
HCE-4MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGjWSJdKSzVyPUGuOlA5PSEQvF2=MonxV2FPT0WU
HT-144NV\3S5RbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGPPUJVKSzVyPUGuOlMyQSEQvF2=NEXlTGpUSU6JRWK=
NCI-H524NUXPSXFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTFwNkSzNFch|ryPMXnTRW5ITVJ?
NKM-1MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTFwNki2OkDPxE1?NFzwWpZUSU6JRWK=
KURAMOCHIM1mxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1jy[WlEPTB;MT62PVU4OyEQvF2=NYLO[XdvW0GQR1XS
NCI-H187NYD3TXppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{DIXGlEPTB;MT63NFA{PiEQvF2=NVjHSY06W0GQR1XS
U-266MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVjhVVBxUUN3ME2xMlc{QDR{IN88US=>MVjTRW5ITVJ?
BL-41NEja[m1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYnV[GVpUUN3ME2xMlc3Ojd{IN88US=>M{j4O3NCVkeHUh?=
SK-N-DZM3W4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHf2NppKSzVyPUGuO|g{ODlizszNNGHLeXpUSU6JRWK=
DaudiMnHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTFwN{i5Olch|ryPNH\ncIlUSU6JRWK=
CPC-NMnHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTFwOEWwPVYh|ryPM{[2UHNCVkeHUh?=
EM-2MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX3KTIl6UUN3ME2xMlg2OSEQvF2=MmjHV2FPT0WU
HCC1187NFfE[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTFwOE[yOFEh|ryPNFz5V2VUSU6JRWK=
LP-1MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4TjWWlEPTB;MT64O|E1OyEQvF2=MlvDV2FPT0WU
CAS-1MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVmwSGUxUUN3ME2xMlk5Ojl7IN88US=>MnP1V2FPT0WU
NB7Ml7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRTJwMEC1OVUh|ryPNWHFWWFQW0GQR1XS
VA-ES-BJNXLpe|NoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\ofWlEPTB;Mj6wNVUyOyEQvF2=MnPKV2FPT0WU
SNU-C2BM4\OTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRTJwMEOzOVEh|ryPMnG0V2FPT0WU
LOXIMVIMl:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPRN2lKSzVyPUKuNFY4QDZizszNNX;O[lduW0GQR1XS
NCI-H1581MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVnYXppsUUN3ME2yMlEyPTV7IN88US=>MoXEV2FPT0WU
IST-SL2M1ez[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1XMfmlEPTB;Mj6xNlQ1PSEQvF2=M3fQSHNCVkeHUh?=
NOMO-1NGTKbW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2fu[GlEPTB;Mj6xO|Y5OyEQvF2=NInQS3VUSU6JRWK=
TE-6MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2G4SGlEPTB;Mj6xPVA2KM7:TR?=NWDBZZdJW0GQR1XS
NCI-H526MmmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTJwMUmxOFEh|ryPNHzHSVJUSU6JRWK=
MSTO-211HNHrnWFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mo\vTWM2OD1{LkKwNFQyKM7:TR?=MVvTRW5ITVJ?
LS-513MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2LrNGlEPTB;Mj6yNlI3QSEQvF2=MX7TRW5ITVJ?
NCI-SNU-1MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTJwM{OyOVYh|ryPM4fqbHNCVkeHUh?=
BB65-RCCMlOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUPzVpF2UUN3ME2yMlM4PDl|IN88US=>NGXIT4JUSU6JRWK=
GT3TKBMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUXhN5B4UUN3ME2yMlM6QTd{IN88US=>NYK2UZJwW0GQR1XS
OS-RC-2MljQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M13OSWlEPTB;Mj60NlM1OSEQvF2=MWDTRW5ITVJ?
NCI-H2126MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX65fXF3UUN3ME2yMlQ{Pjd2IN88US=>NXi2SpVjW0GQR1XS
SK-UT-1NEXZWlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWrs[GZtUUN3ME2yMlQ4PDZ5IN88US=>M3PnUHNCVkeHUh?=
DMS-114MoTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHzLVZlKSzVyPUKuOlE2OjRizszNM3LCSHNCVkeHUh?=
ONS-76NU[1ZWJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTJwNkO2OFEh|ryPM2Dm[3NCVkeHUh?=
8-MG-BAMl\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2TUemlEPTB;Mj62OVQyPCEQvF2=NX[2RY9QW0GQR1XS
BOKUMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\xZ2lEPTB;Mj63Nlc3PCEQvF2=NXvPVGdmW0GQR1XS
LAMA-84MkHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTJwN{m5NVIh|ryPMk\JV2FPT0WU
ES1M4jHT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTJwOEG4NFQh|ryPNF75R2FUSU6JRWK=
NCI-H1395Mn\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGD4O41KSzVyPUKuPFIxOTJizszNNX[3WlZPW0GQR1XS
A388NH3Qe4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUDvc|ZNUUN3ME2yMlk3OTdizszNMV3TRW5ITVJ?
NCCITNYnxVHhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYTGR2d2UUN3ME2zMlA5QDZ{IN88US=>MonxV2FPT0WU
HD-MY-ZNUX5elVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfaSHFWUUN3ME2zMlE{OjB|IN88US=>NGfRXItUSU6JRWK=
NCI-H510AMlyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEixWFJKSzVyPUOuNVg6PDNizszNNFvPUIJUSU6JRWK=
NCI-N87NGCwSldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnzxTWM2OD1|LkKwNFIh|ryPNEjPUoxUSU6JRWK=
SCLC-21HM{L5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIjlenZKSzVyPUOuNlY5PTlizszNNUDH[pk3W0GQR1XS
SH-4NXPPS5k3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3LZXGlEPTB;Mz6yPFc6PyEQvF2=MnroV2FPT0WU
QIMR-WILNHP3c4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUW4SVZPUUN3ME2zMlMzQDR7IN88US=>MUfTRW5ITVJ?
KM12M3vyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Moi5TWM2OD1|LkOzOVQ1KM7:TR?=Mom4V2FPT0WU
ST486NYHM[oxMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2XaR2lEPTB;Mz61N|g5OyEQvF2=MnW3V2FPT0WU
HC-1NY\pOmFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFu0b5hKSzVyPUOuOlIxOjhizszNNGHYT2tUSU6JRWK=
BV-173NX;Dc2dpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2P1S2lEPTB;Mz62OFA5QCEQvF2=M4[wd3NCVkeHUh?=
EW-24MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHuRohGUUN3ME2zMlY3PDN2IN88US=>MkmwV2FPT0WU
LU-65NUnTPYgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTNwNki3NUDPxE1?Mn;oV2FPT0WU
ECC4MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEnrNGxKSzVyPUOuO|c2PiEQvF2=MkjTV2FPT0WU
ARH-77NFX1[WlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3rjOmlEPTB;ND6xNVA3PyEQvF2=M4LzVHNCVkeHUh?=
BC-3M1zvUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3Y[5ZtUUN3ME20MlE{ODZ6IN88US=>MX7TRW5ITVJ?
SNB75MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTRwMk[xPUDPxE1?NYXufIh1W0GQR1XS
MEG-01NH\WfGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWnJR|UxRTRwMke0NVkh|ryPMmSzV2FPT0WU
NCI-H1417NH;Kd45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTRwMki0OFMh|ryPM3[5O3NCVkeHUh?=
MDA-MB-134-VIMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlnTTWM2OD12LkOwOlAyKM7:TR?=MWTTRW5ITVJ?
BeckerNX7uc5RTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUHJR|UxRTRwNEezN|Yh|ryPMofkV2FPT0WU
DMS-153NVPIS3lbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV7SXlNCUUN3ME20MlY3PDd3IN88US=>NXG2ZVk2W0GQR1XS
TGBC1TKBM1vRNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;LdIdyUUN3ME20MlY5PTF3IN88US=>NVPrfHA5W0GQR1XS
EW-3NFnZWZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1u4PWlEPTB;ND63OlI1QCEQvF2=NICzZ|JUSU6JRWK=
KE-37MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnnKTWM2OD12Lki2NVk3KM7:TR?=M17wTHNCVkeHUh?=
NCI-H23NULPZpJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXWb|k2UUN3ME20Mlg4OjJ5IN88US=>MlO1V2FPT0WU
MC116NGDhXIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3j6OGlEPTB;ND65OFEzPiEQvF2=M13scHNCVkeHUh?=
NH-12NWPBS4dtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1nKWGlEPTB;ND65OlQ{QSEQvF2=Mo\kV2FPT0WU
CTB-1NVT2ZWR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1TEWmlEPTB;ND65O|czOSEQvF2=Mo\PV2FPT0WU
KM-H2NWjaO2RnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVrJR|UxRTVwMEWzNlMh|ryPMVzTRW5ITVJ?
MOLT-4M4jTcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoW1TWM2OD13LkGxPFMh|ryPNIOxXVNUSU6JRWK=
NCI-H2141MkjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX2wNGI4UUN3ME21MlE1OjZ6IN88US=>NFrHPVVUSU6JRWK=
EB-3M4nLSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVjTdWhkUUN3ME21MlE4PTB2IN88US=>MXXTRW5ITVJ?
NCI-H1522MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEi4OFVKSzVyPUWuNlY{OjJizszNNGT6WHZUSU6JRWK=
MRK-nu-1MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTVwNEO2N|Mh|ryPMmHDV2FPT0WU
no-11M3fIcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUO5bmM{UUN3ME21MlQ4ODh5IN88US=>M2C4PHNCVkeHUh?=
CESSNVvaVHRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTVwNUiwN|Qh|ryPMYnTRW5ITVJ?
KMOE-2NVnJemRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFruR3FKSzVyPUWuOVg3PTlizszNNGnxPYVUSU6JRWK=
REHM4fIUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUPJR|UxRTZwMkW2NVgh|ryPMmjxV2FPT0WU
KU812MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTZwNEK3PVEh|ryPNITrdphUSU6JRWK=
SK-N-FIMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlraTWM2OD14Lk[wOlc1KM7:TR?=NW[ybmU4W0GQR1XS
MMAC-SFNGXZcmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHXwTXlKSzVyPUeuNFY1QTJizszNNUGyXVR5W0GQR1XS
RCC10RGBM1rS[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2nRcmlEPTB;Nz6yNlk4PyEQvF2=M3\LOHNCVkeHUh?=
NCI-H322MMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWHlO5h2UUN3ME23MlM{OzN3IN88US=>NU[1PJdVW0GQR1XS
NB6M4H4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHHycItKSzVyPUeuOVQ5QTlizszNNGjoZ|hUSU6JRWK=
MN-60NVPLSYxIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEfpOpNKSzVyPUeuOlkzOTVizszNM3e3UnNCVkeHUh?=
NCI-H1092MnjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRThwMEG3N|Qh|ryPM2GzXnNCVkeHUh?=
EKVXNX[1N2UxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGHrWFNKSzVyPUiuOFcxPjZizszNMk\YV2FPT0WU
D-263MGNUfRNlV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXLrfmNtUUN3ME24MlU2Ozl4IN88US=>NHnM[otUSU6JRWK=
NCI-H209MlfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1XDTWlEPTB;OD62OFAxPiEQvF2=M2nYSnNCVkeHUh?=
IST-SL1M4LBOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX6zbHcxUUN3ME24Mlg6QDl{IN88US=>M3fRU3NCVkeHUh?=
ACNNXWxZVFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkKxTWM2OD17LkG5NVU4KM7:TR?=NIjWVXRUSU6JRWK=
MHH-PREB-1NVn1T4JWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmHLTWM2OD17LkKxNlE6KM7:TR?=MUPTRW5ITVJ?
EW-11NVfwT4g1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFj4TIdKSzVyPUmuOlU{QTZizszNM1HqdnNCVkeHUh?=
KASUMI-1NUXkRmR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV;4ZW4xUUN3ME25Mlc5PzdizszNMVLTRW5ITVJ?
KINGS-1MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnnxTWM2OD1zMD6yN|Q4KM7:TR?=MUPTRW5ITVJ?
EVSA-TNXXJbGpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlqxTWM2OD1zMD6zNVkzKM7:TR?=NWS5PFg{W0GQR1XS
DSH1NF7GeWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTFyLkO5O|Ih|ryPMkD6V2FPT0WU
COLO-824MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTFyLki2Olkh|ryPNInJZZFUSU6JRWK=
K052MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3zRcmlEPTB;MUCuPVMzOiEQvF2=M1rNbXNCVkeHUh?=
SK-MEL-2NVXkXnN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEHGUVJKSzVyPUGwMlk6OzlizszNMkLEV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo After 4 weeks of treatment with TAE684 at 3 and 10 mg/kg, there is a significant delay in lymphoma development and 100- to 1,000-fold reduction in luminescence signal, without any signs of compound- or disease-related toxicity in Karpas-299 lymphoma model. TAE684 treatment also induces disease regression in established Karpas-299 lymphomas and down-regulates CD30 expression. [1] TAE684 also shows impressive antitumor activity against H3122 CR xenograft tumors. [2] Furthermore, treatment with TAE684 improves the rough eye phenotype of both ALK mutants, especially that seen with ALKR1275Q, whereas Crizotinib has little effect on either phenotype. [3]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

In vitro Enzyme Assays. All in vitro enzyme assays are done at Upstate Biotechnology with the exception of InsR and IGF-1R. To determine the IC50 of TAE684 against InsR and IGF-1R a homogeneous time-resolved fluorescence assay is performed. ATP (10 mM) and 20 mg/ml biotinylated PolyEY (Glu, Tyr 4:1) are combined with 50 nL of serial dilutions of TAE684 (10-500 nM) and 4 ng of InsR enzyme in the presence of the kinase reaction buffer (20 mM Tris譎Cl, pH 7.5/10 mM MgCl2/3 mM MnCl2/1 mM DTT/10 mM NaVO4/0.1 mg/ml of BSA). Assays are incubated for 1 hour at ambient temperature. Reactions are terminated by adding 10 mL of the detection solution containing 50 mM EDTA, 500 mM KF, 0.5 mg/ml of BSA, 5 mg/mL Eu3+ cryptate-labeled anti-phosphotyrosine antibody Mab PT66-K, and 5 mg/mL Streptavidin-XLent. The reaction is incubated for half an hour, and fluorescence signals are read on Analyst GT.

Cell Assay: [1]

Cell lines Luciferase-expressing Karpas-299, SU-DHL-1, and Ba/F3 cells and transformed Ba/F3 stably expressing NPM-ALK, Bcr-Abl, or TEL-kinase fusion constructs.
Concentrations 1 nM-10 μM
Incubation Time 2–3 days
Method Cells are seeded in 384-well plates (2.5×104 cells per well) and incubated with serial dilutions of TAE684 or DMSO for 2–3 days. Luciferase expression is used as a measure of cell proliferation/survival and is evaluated with the Bright-Glo Luciferase Assay System. IC50 values are generated by using XLFit software.

Animal Study: [1]

Animal Models Karpas-299 xenografts are established in 4- to 6-week old female Fox Chase SCIDBeige mice.
Formulation Resuspended in 10% 1-methyl-2-pyrrolidinone/90% polyethylene glycol 300 solution
Dosages 1, 3, and 10 mg/kg
Administration Once daily by oral gavage for 3 weeks

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Galkin AV, et al. Proc Natl Acad Sci U S A, 2007, 104(1), 270-275.

[2] Katayama R, et al. Proc Natl Acad Sci U S A, 2011, 108(18), 7535-7540.

view more

Chemical Information

Download TAE684 (NVP-TAE684) SDF
Molecular Weight (MW) 614.2
Formula

C30H40ClN7O3S

CAS No. 761439-42-3
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 3 mg/mL (4.88 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol, pH 4 10 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related ALK Products

  • PF-06463922

    PF-06463922 is a potent, dual ALK/ROS1 inhibitor with Ki of <0.02 nM, <0.07 nM, and 0.7 nM for ROS1, ALK (WT), and ALK (L1196M), respectively. Phase 1.

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • R428 (BGB324)

    R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).

  • GSK1838705A

    GSK1838705A is a potent IGF-1R inhibitor with IC50 of 2.0 nM, modestly potent to IR and ALK with IC50 of 1.6 nM and 0.5 nM, respectively, and little activity to other protein kinases.

    Features:A small-molecule kinase inhibitor of IGF-1R and the insulin receptor.

  • Alectinib (CH5424802)

    Alectinib (CH5424802) is a potent ALK inhibitor with IC50 of 1.9 nM in cell-free assays, sensitive to L1196M mutation and higher selectivity for ALK than PF-02341066, NVP-TAE684 and PHA-E429.

  • AP26113

    AP26113 is a potent ALK inhibitor with IC50 of 0.62 nM in a cell-free assay, demonstrated ability overcome Crizotinib resistance mediated by a L1196M mutation. Phase 2.

    Features:At least 10-fold more potent and selective in ALK inhibition relative to crizotinib.

  • ASP3026

    ASP3026 is a novel and selective inhibitor for ALK with IC50 of 3.5 nM. Phase 1.

  • AZD3463

    AZD3463 is a novel orally bioavailable ALK inhibitor with Ki of 0.75 nM, which also inhibits IGF1R with equivalent potency.

  • Ceritinib (LDK378)

    Ceritinib (LDK378) is potent inhibitor against ALK with IC50 of 0.2 nM in cell-free assays, shows 40- and 35-fold selectivity against IGF-1R and InsR, respectively. Phase 3.

    Features:Does not cross react with c-Met, and has an improved in vivo glucose homeostasis profile relative to TAE684. May be active in Crizotinib-relapsed tumors.

  • Gefitinib (ZD1839)

    Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

    Features:A potent EGFR tyrosine kinase inhibitor.

Recently Viewed Items

Tags: buy TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) supplier | purchase TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) cost | TAE684 (NVP-TAE684) manufacturer | order TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us